Updated October 19, 2020
The link in the original post broke.
You might also like:
- - - original post follows below - - -
"Ben Venue Laboratories, the contract drug manufacturer whose quality lapses caused a shortage of Johnson & Johnson's (JNJ) cancer drug Doxil and recalls of numerous other drugs, reached an agreement with U.S. authorities governing the company's efforts to fix the problems.
Ben Venue, a Bedford, Ohio, division of Germany's Boehringer Ingelheim, signed a so-called "consent decree" with the Food and Drug Administration, according to a company statement and court documents filed by the Department of Justice in federal court in Ohio.
The consent decree bars Ben Venue from making and selling certain drugs until the company can demonstrate that it has taken certain steps to correct its manufacturing problems, among other requirements."
'via Blog this'
Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
Posts
1 comment:
You might also like FDA GMP QSR cGMP Training: FDA GMP QSR cGMP Training - popular online training courses by SkillsPlus International Inc.
Post a Comment